关注
Nizar Y. Saad
Nizar Y. Saad
Assistant Professor, The Research Institute at Nationwide Children's Hospital
在 nationwidechildrens.org 的电子邮件经过验证 - 首页
标题
引用次数
引用次数
年份
Major bioactivities and mechanism of action of essential oils and their components
NY Saad, CD Muller, A Lobstein
Flavour and Fragrance Journal 28 (5), 269-279, 2013
3262013
AAV-mediated follistatin gene therapy improves functional outcomes in the TIC-DUX4 mouse model of FSHD
CR Giesige, LM Wallace, KN Heller, JO Eidahl, NY Saad, AM Fowler, ...
JCI insight 3 (22), 2018
672018
Pre-clinical safety and off-target studies to support translation of AAV-mediated RNAi therapy for FSHD
LM Wallace, NY Saad, NK Pyne, AM Fowler, JO Eidahl, JS Domire, ...
Molecular therapy Methods & clinical development 8, 121-130, 2018
642018
Two-codon T-box riboswitch binding two tRNAs
NY Saad, V Stamatopoulou, M Braye, D Drainas, C Stathopoulos, ...
Proceedings of the National Academy of Sciences 110 (31), 12756-12761, 2013
402013
A ribonucleopeptide world at the origin of life
NY Saad
Journal of Systematics and Evolution 56 (1), 1-13, 2018
352018
Human miRNA miR-675 inhibits DUX4 expression and may be exploited as a potential treatment for Facioscapulohumeral muscular dystrophy
NY Saad, M Al-Kharsan, SE Garwick-Coppens, GA Chermahini, ...
Nature communications 12 (1), 1-18, 2021
282021
Riboswitch (T-box)-mediated control of tRNA-dependent amidation in Clostridium acetobutylicum rationalizes gene and pathway redundancy for asparagine and asparaginyl-trnaasn …
NY Saad, B Schiel, M Braye, JT Heap, NP Minton, P Duerre, HD Becker
Journal of Biological Chemistry 287 (24), 20382-20394, 2012
272012
A glyS T-box riboswitch with species-specific structural features responding to both proteinogenic and nonproteinogenic tRNAGly isoacceptors
M Apostolidi, NY Saad, D Drainas, S Pournaras, HD Becker, ...
Rna 21 (10), 1790-1806, 2015
212015
The DUX4 protein is a co‐repressor of the progesterone and glucocorticoid nuclear receptors
J Quintero, NY Saad, SM Pagnoni, DK Jacquelin, LV Gatica, SQ Harper, ...
FEBS letters 596 (20), 2644-2658, 2022
52022
Engineering more efficient therapeutic miRNAs for FSHD gene therapy
NY Saad, NK Pyne, J Copeland, SQ Harper
MOLECULAR THERAPY 28 (4), 113-113, 2020
22020
P65 Development of therapeutic extracellular vesicle enveloped-AAV vectors for muscle gene therapy
J Kauffman, N Saad
Neuromuscular Disorders 33, S75, 2023
12023
Post‐Translational Modifications of the DUX4 Protein Impact Toxic Function in FSHD Cell Models
RN Knox, JO Eidahl, LM Wallace, SG Choudury, A Rashnonejad, ...
Annals of neurology 94 (2), 398-413, 2023
12023
Investigation of the natural miRNA miR-675 as a prospective RNAi-based gene therapy product for facioscapulohumeral muscular dystrophy (FSHD)
NY Saad, GA Chermahini, M Al-Kharsan, S Garwick-Coppens, SQ Harper
MOLECULAR THERAPY 28 (4), 468-468, 2020
12020
Compositions and methods for treating disease associated with dux4 overexpression
N Saad, SQ Harper
US Patent App. 18/274,327, 2024
2024
Acknowledgment to the Reviewers of Life in 2022
LE Office
Life 13 (2), 2023
2023
P. 143 Investigation of human bone marrow mesenchymal stem cell-derived extracellular vesicles as therapeutic agents for Facioscapulohumeral muscular dystrophy
L Wallace, S Harper, N Saad
Neuromuscular Disorders 32, S106, 2022
2022
Investigation of Human Bone Marrow Mesenchymal Stem Cell-Derived Extracellular Vesicles as Therapeutic Agents for Facioscapulohumeral Muscular Dystrophy (FSHD)
LM Wallace, SQ Harper, NY Saad
MOLECULAR THERAPY 30 (4), 463-463, 2022
2022
Translating DUX4-Targeted RNAi-Based Gene Therapy for FSHD
LM Wallace, T Riley, N Saad, MJ Guggenbiller, GA Chermahini, ...
MOLECULAR THERAPY 30 (4), 502-502, 2022
2022
Engineering More Efficient Therapeutic miRNAs for FSHD Gene Therapy
NY Saad, LM Wallace, NK Pyne, J Copeland, M Guggenbiller, ...
MOLECULAR THERAPY 30 (4), 279-279, 2022
2022
Acknowledgment to Reviewers of Life in 2021
Life Editorial Office
Life 12 (2), 199, 2022
2022
系统目前无法执行此操作,请稍后再试。
文章 1–20